Stream Link 1 PM: https://globalmeet.webcasts.com/starthere.jsp?ei=1676851&tp_key=3ac8b0837b
Stream Link 8 PM: https://globalmeet.webcasts.com/starthere.jsp?ei=1676852&tp_key=fc3a24da52
This activity is part 2 of a 3-part webinar curriculum and includes a Powered by Patients™ video interview.
Program Description
Anti-vascular endothelial growth factor (anti-VEGF) agents act as inhibitors to the growth of new blood vessels, which can translate to potentially improved visual outcomes and slowed disease progression in ophthalmologic conditions, including age-related macular degeneration (AMD) and diabetic macular edema (DME). There are complexities that differentiate this class from other recently advanced ophthalmologic therapies. While effective, frequent anti-VEGF injections can be burdensome for patients, leading to potential nonadherence and impacting treatment success. This webinar explores strategies for specialty pharmacists to support the ophthalmology team in optimizing anti-VEGF therapy for patients with AMD and DME. The discussion will delve into the mechanisms of action of approved anti-VEGF agents, analyzing real-world data on their safety and efficacy in both conditions, as well as current guideline-recommended dosing approaches to individualize treatment plans. A Powered by Patients™ interview will be included within the presentation, featuring the perspective of an individual living with AMD/DME and their experience with anti-VEGF injections.
Target audience: Specialty pharmacists
Type of activity: Application
Release date: August 8, 2024
Expiration date: October 8, 2024
Time to complete activity: 1.0 hour
Learner level: Foundational
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the mechanisms of action of available anti-vascular endothelial growth factor (VEGF) agents for age-related macular degeneration (AMD) and diabetic macular edema (DME) based on real-world safety and efficacy data
- Compare the current guideline recommendations for anti-VEGF dosing strategies in the treatment of AMD
- Explore patient-specific treatment plans that incorporate individualized anti-VEGF therapy selection in DME
- Identify the potential ocular and systemic adverse effects associated with anti-VEGF therapy in AMD and DME and strategies for their identification, prevention, and management
